Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing immunomodulatory therapies to prevent organ rejection and treat amyotrophic lateral sclerosis (ALS). The company’s lead compound, tegoprubart, is an anti-CD40L antibody designed to target the CD40 Ligand pathway to protect transplanted organs, specifically prioritizing kidney transplantation programs. Eledon acquired Anelixis Therapeutics, Inc. in September 2020 to obtain the intellectual property for tegoprubart. Prior to this acquisition, the company focused on developing medicines for ear, nose, and throat (ENT) disorders, but suspended these activities in 2020 after its lead program failed to meet primary efficacy endpoints. The company serves the transplant medicine market, aiming to address the limitations of current calcineurin inhibitor-based immunosuppression regimens, which are associated with long-term side effects such as nephrotoxicity and diabetes. Eledon’s strategy centers on optimizing the clinical and commercial value of tegoprubart for allograft and xenograft organ protection, with a specific focus on extending the functional life of transplanted kidneys.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage eledon.com
Sector Healthcare IR page ir.eledon.com
Tags
immunology, organ transplantation, kidney transplant, amyotrophic lateral sclerosis, anti-cd40l, antibody therapeutics, immunosuppression, clinical-stage, tegoprubart, Anelixis Therapeutics Inc.
Press page —

Metrics

Valuation  
Market cap $ 206.049M
Market cap (USD) $ 206.049M
P/E -3.47
PEG —
P/BV 6.69
P/S —
P/OCF -2.63
P/FCF -3.31
Dividend yield —
Turnover / mcap —
Returns  
ROE -45.8%
ROI -77.9%
ROIC -106.6%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 62
Quality score -83.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Assets 169.009M 177.405M 89.066M 92.793M 170.548M 197.185M 10.931M 17.026M 20.892M 29.761M 67.974M 107.744M 32.287M
Net profit -45.617M -36.184M -40.326M -87.966M -34.506M -22.811M -16.011M -14.065M -13.116M -37.959M -45.087M -23.296M -15.725M
Free cash flow -62.341M -47.271M -39.527M -28.424M -28.913M — — — — -36.537M -41.801M -21.146M -15.499M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 1.51 4.12 1.8 2.28 4.41 15.4 0.58 1.6 4.06 — — — —
Price performance 12m -0.63 1.29 -0.21 -0.48 -0.71 25.58 -0.64 -0.61 — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — — 324,000 144,000 769,000 746,000 383,000 954,000 641,000
Cash and deposits (USD) 23.2M 17.2M 13M 8.79M 114M 84.8M 56.4M 4.61M 20.5M 22.8M
Right-of-use assets (USD) — — — 316,000 138,000 768,000 739,000 365,000 926,000 613,000
Cash flow detail
Operating cash flow (USD) -36.5M -14.9M -11.9M -13.9M -15.2M -28.9M -28.4M -39.5M -47.3M -62.3M
Purchases of property, plant and equipment (USD) -17,000 — — — — — — — — —
Change in payables (cash effect) (USD) -778,000 -1.96M 1.09M -1.39M -39,000 2.14M 2.08M — — —
Income taxes paid (cash effect) (USD) — — — — — — — — — -28,000
Share-based compensation (USD) 3M 579,000 1.54M 1.31M 3.17M 7.9M 8.15M 6.55M 13.1M 10.5M
Free cash flow (OCF - PPE - intangibles) (USD) -36.5M — — — — — — — — —
Income detail
Research and development expense (USD) 25M 2.02M 6.82M 8.13M 6.13M 23.7M 27.1M 30.3M 52M 66.3M
↳ 5y CAGR -22.8% -11.0% -11.0% -28.4% -1.1% +68.0% +34.8% +44.9% +61.0%
Total comprehensive income (USD) -37.9M — — — — — — — -36.2M -45.6M
Comprehensive income to owners (USD) -37.9M — — — — — — — -36.2M -45.6M
Reported Mar 3, 2017 Apr 2, 2018 Mar 28, 2019 Mar 17, 2020 Mar 31, 2021 Mar 24, 2022 Mar 30, 2023 Mar 28, 2024 Mar 19, 2026 Mar 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Planned global Phase 3 LEGACY trial of tegoprubart in kidney transplantation remains on track to initiate in Q4 2026

FDA cleared the Company’s IND application for a planned registrational path study of tegoprubart in islet cell transplantation for patients with type 1 diabetes

FDA Fast Track designation granted to tegoprubart for the prevention of rejection in kidney transplantation

Cash, cash equivalents and short-term investments of $69.7 million with cash runway into Q2 2027

IRVINE, Calif., November 12, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its third quarter 2026 operating and financial results and provided recent business highlights.

“We continue to execute across our key strategic priorities and make meaningful progress in the tegoprubart clinical program across multiple transplant types, including plans to initiate our global Phase 3 LEGACY trial in kidney transplantation by year end,” said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon.

October 26, 2026

PDF Version

Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom occurrence

Statistically significant improvement on the KDQOL-SF Symptoms and Problems Scale among tegoprubart-treated patients through 12 months following kidney transplantation versus tacrolimus

Results further validate the differentiated clinical profile of tegoprubart and potential to transform standard of care in kidney transplantation

IRVINE, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced new positive patient-reported outcomes data from the Phase 2 BESTOW clinical trial of tegoprubart, its novel investigational immunosuppression therapy. The data showed significant, sustained improvements in health-related quality of life and symptom burden through 12 months compared with standard of care tacrolimus following kidney transplantation. The results were featured in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026 Annual Meeting held October 21-25, 2026, in Denver, Colorado.

“The patient-reported outcomes presented at ASN Kidney Week provide perhaps the clearest picture yet of what tegoprubart’s differentiated profile means for transplant patients in everyday life,” said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. “We previously reported encouraging BESTOW results across efficacy, kidney function and safety measures, which alone strengthened our belief in tegoprubart. The additional findings presented demonstrate that these clinical outcomes were accompanied by substantial and importantly sustained improvements in quality of life and reductions in transplant-related symptom burden. Giving transplant patients an effective, safer and more tolerable alternative to tacrolimus addresses one of the most important unmet needs in organ transplantation, and collectively, these data further support the potential of tegoprubart to become a transformative new treatment option for kidney transplant recipients.”

“Success after kidney transplantation is measured not only by preventing rejection and preserving graft function, but also by how patients feel and function in their everyday lives,” said presenting author Andrew Adams, M.D., Ph.D., Professor of Surgery and Chief, Division of Transplantation, John S. Najarian Surgical Chair in Clinical Transplantation, Department of Surgery, University of Minnesota. “What is particularly compelling about these BESTOW results is the consistency of the patient-reported benefits when treated with tegoprubart compared with tacrolimus following kidney transplant. We observed broad improvements in quality-of-life measures together with remarkably favorable outcomes in transplant-specific symptom reporting. The extent of separation between treatment groups suggests patients receiving tegoprubart may experience meaningful quality of life advantages while maintaining strong clinical outcomes as previously reported from BESTOW.”

Patient-Reported Outcomes Results

Patient-reported outcomes were assessed using the Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSD-59R) and the Kidney Disease Quality of Life Short Form (KDQOL-SF) Symptoms and Problems Scale, both validated measures of symptom burden. Baseline scores were similar between treatment groups. Collectively, the consistency of findings across both the KDQOL-SF and MTSOSD-59R assessments suggests that reductions in transplant-related symptom burden with tegoprubart may contribute to the improvements observed in patient-reported quality of life and further supports the differentiated clinical profile of tegoprubart compared to tacrolimus observed in the Phase 2 BESTOW clinical trial.

On the MTSOSD-59R assessment, tegoprubart-treated patients reported continued reductions in symptom occurrence from baseline at Months 6 and 12, whereas symptom occurrence in the tacrolimus arm initially declined through Month 6 before returning to slightly above baseline levels at Month 12.

Total MTSOSD-59R Scores represent symptom occurrence (higher scores reflect greater symptom occurrence)

Total MTSOSD-59R

CI, confidence interval; KDQOL-SF, Kidney Disease Quality of Life Short Form; MTSOSD-59R, Modified Transplant Symptom Occurrence Scale- 59 Items Revised; SEM, standard error of the mean; tac, tacrolimus; tego, tegoprubart.

Tegoprubart demonstrated greater symptom improvement than tacrolimus in 22 of 23 domains where differential improvement was observed, including neurological, gastrointestinal, metabolic, and physical symptom categories. In addition, tacrolimus demonstrated greater symptom worsening in 22 of 22 domains where differential symptom worsening was observed.

On the KDQOL-SF assessment, kidney transplant patients treated with tegoprubart demonstrated improvements from baseline across all five subscales through Month 12. In the KDQOL-SF scale, a change of 3-5 points can be considered clinically significant, and tegoprubart was thus associated with a clinically and statistically significant improvement in the symptoms and problems subscale compared with tacrolimus at Month 12, with mean changes from baseline of 9.0 and 3.3 points, respectively (p<0.05). Consistent with these findings, the SF-12 mental component summary score increased by 1.5 points in the tegoprubart arm compared to a decline of 1.6 points in the tacrolimus arm, representing a 3.1-point between-group difference.

KDQOL-SF: Change from Baseline

a Higher scores indicate better HRQoL; a change of 3–5 points can be considered clinically significant1. Baseline values were similar across all outcomes. *p < 0.05. HRQoL, health-related quality of life; KDQOL-SF, Kidney Disease Quality of Life Short-Form instrument; SEM, standard error of the mean; SF-12, 12-item short-form survey; tac, tacrolimus; tego, tegoprubart.1. KDOQI. Am J Kidney Dis 2007;50:471–530.

Details of the oral presentation at ASN Kidney Week 2026 are below:

Title: Patient-Reported Outcomes in the Phase 2 BESTOW Trial Comparing Tegoprubart to Tacrolimus in Kidney Transplant Recipients **Presenter:**Andrew B. Adams, M.D., Ph.D., Department of Surgery, University of Minnesota Medical School; Minneapolis, Minnesota **Abstract Publication Number:**FR-OR084 **Session Title:**The Changing Landscape of Kidney Transplantation: Clinical Innovation, Outcomes, and Healthy Policy Session Date and Time: Friday, October 23, 2026, from 4:30 p.m. to 6:00 p.m. MDT **Session Room:**Mile High Ballroom 4A (Convention Center) Presentation Time: 4:40 p.m. to 4:50 p.m. MDT

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40L biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; X

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company’s future expectations, plans and prospects, including statements about planned clinical trials, the development of product candidates, expected timing for initiation of future clinical trials, expected timing for receipt of data from clinical trials, as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,” “targets,” “looks forward,” “could,” “may,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Specifically, our ability to achieve our anticipated future development and corporate milestones depends on our ability to obtain additional financing on acceptable terms. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: our short operating history and shifts in our business strategy; our operating losses since inception; our need for additional funding to develop our lead drug candidate and our ability to secure additional funding on acceptable terms or at all; the impact of issuances of our common stock, including in the possibility of dilution or a decline in our stock price; our ability to successfully develop our product candidates; unfavorable global economic and financial market conditions; the regulatory environment of our business and our ability to obtain required regulatory approvals; results of non-clinical studies and clinical trials, and risks that non-clinical studies or early clinical trials may not be predictive of results of later-stage clinical trials; delays or difficulties in enrollment of patients in clinical trials; our ability to attract and retain our executives and key employees; legislation of the pharmaceutical and healthcare industries; cybersecurity and data privacy risks; the ability of our products to achieve marketing approval; competition in our industry; our ability to obtain insurance coverage; our dependence on contract research organizations; our ability to protect our intellectual property; public health crises; our ability to maintain proper and effective internal control over financial reporting and other risks disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 19, 2026. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company’s actual results to differ materially from the forward-looking statements contained herein, are discussed in our Annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:

Stephen Jasper Gilmartin Group (858) 525 2047 [email protected]

Media Contact:

Jenna Urban CG Life (212) 253 8881 [email protected]

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/579abadf-4871-4465-9e03-706a758fa40e

https://www.globenewswire.com/NewsRoom/AttachmentNg/cb7f0d46-3ad7-4f31-a619-183f43abf9ed

Primary Logo

Total MTSOSD-59R

Scores represent symptom occurrence(higher scores reflect greater symptom occurrence)
KDQOL-SF: Change from Baseline

ᵃHigher scores indicate better HRQoL; a change of 3–5 points can be considered clinically significant¹. Baseline values were similar across all outcomes. *p < 0.05. HRQoL, health-related quality of life; KDQOL-SF, Kidney Disease Quality of Life Short-Form instrument; SEM, standard error of the mean; SF-12, 12-item short-form survey; tac, tacrolimus; tego, tegoprubart.1. KDOQI. Am J Kidney Dis 2007;50:471–530.

eledon logo

October 5, 2026

PDF Version

IRVINE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation will be featured at the upcoming American Society of Nephrology Kidney Week 2026 Annual Meeting taking place in Denver, CO, from October 21-25, 2026. The oral presentation will highlight patient-reported outcomes from the Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation.

Details of the presentation are below:

Title: Patient-Reported Outcomes in the Phase 2 BESTOW Trial Comparing Tegoprubart to Tacrolimus in Kidney Transplant Recipients

**Presenter:**Andrew B. Adams, M.D., Ph.D., Department of Surgery, University of Minnesota Medical School; Minneapolis, Minnesota

**Abstract Publication Number:**FR-OR084

**Session Title:**The Changing Landscape of Kidney Transplantation: Clinical Innovation, Outcomes, and Healthy Policy

Session Date and Time: Friday, October 23, 2026, from 4:30PM to 6:00PM MDT

**Session Room:**Mile High Ballroom 4A (Convention Center)

Presentation Time: 4:40PM to 4:50 PM MDT

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40L biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; X

Investor Contact:

Stephen Jasper Gilmartin Group (858) 525 2047 [email protected]

Media Contact:

Jenna Urban CG Life (212) 253 8881 [email protected]

Primary Logo

eledon logo

Prompts

Eledon Pharmaceuticals, Inc. (ticker ELDN), listed in United States.

Company History

Date Change Detail
Dec 16, 2020 Renamed NOVUS THERAPEUTICS, INC. → ELEDON PHARMACEUTICALS, INC.
Feb 23, 2017 Renamed TOKAI PHARMACEUTICALS INC → NOVUS THERAPEUTICS, INC.

ETFs Holding Eledon Pharmaceuticals, Inc.

ETF Weight in ETF Shares Market value As of
RESM 0.01% 86 $ 338.84 Jun 30, 2026
MSSM 0.00% 7,790 $ 23.214K Aug 31, 2026
DFAS 0.00% 244,973 $ 579.361K Nov 12, 2026
DFAC 0.00% 45,699 $ 108.078K Nov 12, 2026
DCOR 0.00% 4,274 $ 10.108K Nov 12, 2026